Helus Pharma stock jumps on Phase 3 enrollment completion By Investing.com
Helus Pharma (NASDAQ:HELP) shares rose 12.4% after the company said it completed enrollment in its APPROACH Phase 3 trial of HLP003 for major depressive disorder. The study enrolled 223 adults; topline data are expected in Q4 2026. APPROACH is one of two pivotal trials, with EMBRACE ongoing.
How this was made
The 30-second read
Why it matters
Completion of enrollment ahead of schedule is a concrete operational milestone that can improve confidence in trial execution and keep the Q4 2026 topline timeline in focus.
Market read
Traders can reassess the probability-weighted path to Phase 3 topline in Q4 2026 after a same-day enrollment completion update.
What to watch
The article does not provide interim efficacy results from APPROACH, and it highlights only expected topline timing, leaving uncertainty around effect size versus placebo and the status of the second pivotal trial (EMBRACE).
Background
Helus Pharma is running its Phase 3 PARADIGM Program with two pivotal trials, APPROACH and EMBRACE, for HLP003 in major depressive disorder.
Ticker impact
Helus Pharma shares jumped 12.4% after it said enrollment is complete in its APPROACH Phase 3 pivotal study of HLP003 for MDD.
Near-term upside bias likely persists while traders price in Q4 2026 topline timing; volatility may rise into interim readouts and EMBRACE/EXTEND milestones.
The article provides a concrete, company-specific catalyst (Phase 3 enrollment completion) and a specific next data window (Q4 2026), which can move risk perception and positioning.
Market effects
Supports sentiment for psychedelic-adjacent/deuterated psilocin development programs and MDD trial progress narratives.
Limited, primarily affects US small/mid-cap biotech sentiment rather than broad regional flows.
Modest, as the catalyst is company-specific and not a cross-market macro/regulatory event.
Counterpoint
Enrollment completion does not guarantee positive efficacy or safety; the market may be over-discounting the probability of success ahead of topline data.
Key entities
- companyHelus Pharma
NASDAQ-listed developer of HLP003, whose Phase 3 APPROACH enrollment completion drove the stock move.
- drug_candidateHLP003
Deuterated psilocin analogue being tested in Phase 3 for major depressive disorder.
- clinical_trialAPPROACH
First pivotal Phase 3 trial in the PARADIGM Program; enrollment completed ahead of schedule.
- clinical_trialEMBRACE
Second pivotal Phase 3 trial; enrollment continues per the article.
- clinical_trialEXTEND
Long-term extension study for safety, durability, and potential redosing.
